Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
about
Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancerFactors influencing adherence to cancer treatment in older adults with cancer: a systematic reviewRacial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic reviewGeographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.Adjuvant therapy use among Appalachian breast cancer survivorsA randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)Adherence to hormone therapy among women with breast cancerEarly discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor.Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.Early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients.Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patientsTamoxifen and CYP2D6: a contradiction of data.Oral anticancer agent medication adherence by outpatientsPerspectives on adherence and persistence with oral medications for cancer treatment.The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer.Patient adherence to aromatase inhibitor treatment in the adjuvant setting.Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer.Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women--an Asian population-based study.Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsBreast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.Adherence to BCR-ABL inhibitors: issues for CML therapy.The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income womenCompliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data.The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot studyEarly discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.Prescription drug coverage: implications for hormonal therapy adherence in women diagnosed with breast cancerPrescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain.Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancerPersistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.
P2860
Q24632347-6DF788C4-D46B-4060-B68E-2921AA9578B3Q26850736-CD20F895-352B-4A9A-93B8-E6395158525AQ28082674-06CEC670-3824-4FF6-97C0-AC1063A8E91BQ30275906-64FC966B-6BC4-460E-A320-A45C9A00A6C0Q30279083-9433DF39-C7CC-49A7-9F26-1554EA6FE5C7Q33618145-44CBFB25-DDD2-4043-B2F5-6C629AE37B08Q33755452-E6F2BEB3-940C-4AB1-B9C1-464C193138BFQ33756969-3032E41A-00A6-480B-B43E-BDEE828541ECQ33795923-B44420A7-9727-4B89-9C64-E0D3B0FC441DQ33885999-550DE076-1EBF-4F66-80C9-F54897AD9F63Q33897610-BB1CAE4C-4A6F-41DF-B234-A4A75AE8F622Q33927985-7D16BA6C-AECE-4547-A9F4-8F631F724853Q34174599-47E51486-813D-4175-9510-04E89F95DDDBQ34193946-8AD16822-4A27-4306-BF38-183B999BE239Q34244463-F2DC6C09-0974-41A2-B7D6-E949B3700E7CQ34293339-B8E646FC-1BDF-4DEA-8091-30057D0C1B59Q34459748-B1709FD8-D230-46CB-96B1-E84DB37229AFQ34736154-06961272-3E23-4EDD-913C-3F03A1932FA7Q34768999-C0ECFF1A-06F9-4B76-9B24-9D160907984AQ35006809-6E2CACE9-FE07-4A8E-A054-769DFE085352Q35059403-510EABAA-F5CF-4A37-84EF-F11E769EA683Q35075218-0ACECB86-CF48-4F7F-A6FA-6E519EFB73D6Q35105896-4F262201-BE97-41D7-B667-61799961C8C9Q35168777-DAE6A546-7854-44FA-950C-DB8E4463F32BQ35186747-99B5947D-EABC-417C-ABCB-50193750D9A3Q35490056-299016FA-51BE-4940-AE2E-6C4CF88EDFA1Q35573002-D3DBA4DC-CDB7-41A2-93C9-EF613FDC3B13Q35595851-7B8056E6-5A9B-47CD-B415-CBD79537FF69Q35742054-9D0694EE-D4BB-4123-A962-4A62924E29E6Q35968741-C2251C9D-B2FA-4585-99F5-B6C87B3D4E2CQ36030885-BDF5469E-2D93-4E34-85AE-5801FF4A68FFQ36087210-95C18E02-A88C-47E1-85F2-32CF1B83AD5DQ36107130-2CDDB630-37FC-4186-95A8-11B150D54D01Q36226324-7FC6F173-EB22-4D19-B082-A3348BF19DB8Q36292773-B703598B-9D48-4F43-809F-1612A0EC14C0Q36300005-12F35E4C-755A-48DF-A6EB-C8D811AD2B71Q36387779-B0A999DC-CBE2-416E-BAB3-D3364B68ECEDQ36406107-7A49BC7B-F97E-4094-9A09-660E16474076Q36408545-CFE40B6D-0A2A-40EE-B3FC-11DFA06CCE93Q36464743-40B2C0DB-AA0E-47B9-B3BF-7109C75E97B1
P2860
Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
2008年學術文章
@zh-hk
name
Cohort study examining tamoxif ...... ty in women with breast cancer
@en
Cohort study examining tamoxif ...... y in women with breast cancer.
@nl
type
label
Cohort study examining tamoxif ...... ty in women with breast cancer
@en
Cohort study examining tamoxif ...... y in women with breast cancer.
@nl
prefLabel
Cohort study examining tamoxif ...... ty in women with breast cancer
@en
Cohort study examining tamoxif ...... y in women with breast cancer.
@nl
P2093
P2860
P356
P1476
Cohort study examining tamoxif ...... ty in women with breast cancer
@en
P2093
A M Thompson
P T Donnan
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604758
P407
P577
2008-11-04T00:00:00Z
P5875
P6179
1006271425